Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9717417 | 0.90 | ITGB3 (0.65) | ITGB3ITGA2BLMNACA1CA2 | |
| SCHEMBL30481056 | 0.88 | LMNA (0.72) | KDM4EALDH1A1LMNANAMPTSMN1; SMN2 | |
| SCHEMBL5657986 | 0.88 | LMNA (0.72) | KDM4EALDH1A1LMNANAMPTSMN1; SMN2 | |
| SCHEMBL23484191 | 0.88 | KDM4E (0.69) | KDM4EALDH1A1EGLN2LMNANAMPT | |
| SCHEMBL13313834 | 0.85 | KDM4E (0.57) | KDM4EALDH1A1EGLN2NAMPTCA1 | |
| SCHEMBL600772 | 0.83 | KDM4E (0.62) | KDM4EALDH1A1EGLN2LMNANAMPT | |
| SCHEMBL9667962 | 0.83 | KDM4E (0.62) | KDM4EALDH1A1EGLN2NAMPTCA1 | |
| SCHEMBL29395845 | 0.83 | KDM4E (0.62) | KDM4EALDH1A1EGLN2LMNANAMPT | |
| Betamipron SCHEMBL4498475 | 0.82 | PRSS1 (0.70) | LMNACA1CA2SMN1; SMN2PRSS1 | |
| Betamipron SCHEMBL605899 | 0.82 | PRSS1 (0.70) | LMNACA1CA2SMN1; SMN2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619000-A1 | PHOSPHORUS-CONTAINING COMPOUNDS FOR TREATING INFLAMMATORY BOWEL DIESEASE | Vivavision Biotech, Inc. (CN) | 2025-09-24 | — | — | EP | claimed |
| WO-2024104422-A1 | PHOSPHORUS-CONTAINING COMPOUNDS FOR TREATING INFLAMMATORY BOWEL DIESEASE | VIVAVISION BIOTECH, INC. (CN) | 2024-05-23 | — | — | WO | claimed |
| EP-4619000-A1 | PHOSPHORUS-CONTAINING COMPOUNDS FOR TREATING INFLAMMATORY BOWEL DIESEASE | Vivavision Biotech, Inc. (CN) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024104422-A1 | PHOSPHORUS-CONTAINING COMPOUNDS FOR TREATING INFLAMMATORY BOWEL DIESEASE | VIVAVISION BIOTECH, INC. (CN) | 2024-05-23 | — | — | WO | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | KDM4E 4157/4885ALDH1A1 1501/4885EGLN2 3093/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | KDM4E 3885/4885ALDH1A1 3543/4885EGLN2 2434/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | KDM4E 4258/4885ALDH1A1 1151/4885EGLN2 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.